T-Therapeutics secures $133M Series B to advance TCR-CD3 bispecifics with major pharma investors
T-Therapeutics announced a $133 million Series B financing round backed by several of the world’s largest drug developers, including Eli Lilly, Johnson & Johnson, Merck KGaA and Sanofi, along with venture partners such as Advent Life Sciences and the British Business Bank.
The capital will fund the company’s two lead bispecific programs: TTX-008, a preclinical candidate targeting multiple tumor types, and TTX-018, a discovery‑stage molecule aimed at inflammatory diseases.
T‑Therapeutics highlighted its Optimus platform, which generates fully human T‑cell receptors for targets previously considered undruggable. CEO Theodora Harold said the programs are first‑in‑class and address significant unmet medical needs.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “T-Therapeutics raises $133M series B for bispecific pipeline with Big Pharma backers in tow”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that